Bifogade filer
Kurs
+2,10%
Likviditet
0,14 MSEK
Kalender
Est. tid* | ||
2025-11-14 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-29 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-16 | N/A | X-dag ordinarie utdelning KDEV 0.00 SEK |
2025-05-15 | N/A | Årsstämma |
2025-04-30 | 08:00 | Kvartalsrapport 2025-Q1 |
2025-02-14 | - | Bokslutskommuniké 2024 |
2024-11-15 | - | Kvartalsrapport 2024-Q3 |
2024-08-30 | - | Kvartalsrapport 2024-Q2 |
2024-05-17 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2024-05-16 | - | Årsstämma |
2024-04-26 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2023-11-17 | - | Kvartalsrapport 2023-Q3 |
2023-08-25 | - | Kvartalsrapport 2023-Q2 |
2023-05-17 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2023-05-16 | - | Årsstämma |
2023-04-28 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-11-18 | - | Kvartalsrapport 2022-Q3 |
2022-08-19 | - | Kvartalsrapport 2022-Q2 |
2022-05-13 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2022-05-12 | - | Årsstämma |
2022-04-29 | - | Kvartalsrapport 2022-Q1 |
2022-02-25 | - | Bokslutskommuniké 2021 |
2022-01-12 | - | Extra Bolagsstämma 2022 |
2021-11-18 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2021-05-05 | - | Årsstämma |
2021-04-29 | - | Kvartalsrapport 2021-Q1 |
2021-02-19 | - | Extra Bolagsstämma 2021 |
2021-02-11 | - | Bokslutskommuniké 2020 |
2020-11-11 | - | Kvartalsrapport 2020-Q3 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-06-16 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2020-06-15 | - | Årsstämma |
2020-05-08 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2020-04-30 | - | Kvartalsrapport 2020-Q1 |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-11-29 | - | Kvartalsrapport 2019-Q3 |
2019-08-30 | - | Kvartalsrapport 2019-Q2 |
2019-06-28 | - | Årsstämma |
2019-05-21 | - | Kvartalsrapport 2019-Q1 |
2019-05-08 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-10-31 | - | Kvartalsrapport 2018-Q3 |
2018-08-16 | - | Kvartalsrapport 2018-Q2 |
2018-04-27 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2018-04-26 | - | Årsstämma |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-02-15 | - | Bokslutskommuniké 2017 |
2017-10-31 | - | Kvartalsrapport 2017-Q3 |
2017-08-29 | - | Kvartalsrapport 2017-Q2 |
2017-05-26 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2017-05-24 | - | Årsstämma |
2017-05-16 | - | Kvartalsrapport 2017-Q1 |
2017-02-28 | - | Bokslutskommuniké 2016 |
2016-11-23 | - | Kvartalsrapport 2016-Q3 |
2016-08-31 | - | Kvartalsrapport 2016-Q2 |
2016-05-26 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2016-05-25 | - | Årsstämma |
2016-05-10 | - | Kvartalsrapport 2016-Q1 |
2016-02-23 | - | Bokslutskommuniké 2015 |
2015-11-17 | - | Kvartalsrapport 2015-Q3 |
2015-08-26 | - | Kvartalsrapport 2015-Q2 |
2015-05-21 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2015-05-20 | - | Årsstämma |
2015-05-06 | - | Kvartalsrapport 2015-Q1 |
2015-02-18 | - | Bokslutskommuniké 2014 |
2014-12-04 | - | Extra Bolagsstämma 2014 |
2014-10-21 | - | Analytiker möte 2014 |
2014-10-21 | - | Kapitalmarknadsdag 2014 |
2014-10-21 | - | Kvartalsrapport 2014-Q3 |
2014-08-21 | - | Kvartalsrapport 2014-Q2 |
2014-05-15 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2014-05-14 | - | Årsstämma |
2014-05-08 | - | Kvartalsrapport 2014-Q1 |
2014-02-19 | - | Bokslutskommuniké 2013 |
2013-11-21 | - | Analytiker möte 2013 |
2013-11-21 | - | Kvartalsrapport 2013-Q3 |
2013-08-22 | - | Kvartalsrapport 2013-Q2 |
2013-05-15 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2013-05-14 | - | Årsstämma |
2013-05-10 | - | Kvartalsrapport 2013-Q1 |
2013-03-20 | - | Extra Bolagsstämma 2013 |
2013-03-20 | - | Bokslutskommuniké 2012 |
2013-03-13 | - | 15-7 2013 |
2012-11-22 | - | Analytiker möte 2012 |
2012-11-22 | - | Kvartalsrapport 2012-Q3 |
2012-08-23 | - | Kvartalsrapport 2012-Q2 |
2012-05-24 | - | X-dag ordinarie utdelning KDEV 0.00 SEK |
2012-05-23 | - | Årsstämma |
2012-05-15 | - | Kvartalsrapport 2012-Q1 |
2012-02-22 | - | Bokslutskommuniké 2011 |
2011-11-29 | - | 15-7 2011 |
2011-11-25 | - | Kvartalsrapport 2011-Q3 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Finans |
Industri | Investeringar |
STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an inotropic agent in the EU.
AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure. The company´s lead asset, AC01, is currently being evaluated in a clinical phase 1b/2a study, GOAL-HF1, in patients with heart failure and reduced ejection fraction (HFrEF).
The European Patent Office (EPO) has granted AnaCardio a joint patent claiming AC01 as an inotropic agent, a type of treatment that can change the force of the hearts contraction. The patent is co-owned by AnaCardio and Helsinn Healthcare SA and provides exclusivity in all major European markets with an expiry date in 2042.
”This additional patent secures the use of our portfolio company AnaCardio’s drug candidate AC01 as an inotropic agent and secures its exclusivity in the European market. This is an important step in strengthening the intellectual property protection and commercial potential for AnaCardio´s unique drug candidate,” says Viktor Drvota, CEO, Karolinska Development.
Karolinska Development’s ownership interest in AnaCardio amounts to 10%.
For further information, please contact:
Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.com.